Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 6 of 6 results for belimumab

  1. Past appeals and decisions

    antipsychotic 24 April 2002 TA397 Systemic lupus erythematosus (active) - belimumab 18 July 2012 TA696 Tafamidis for treating...

  2. Belimumab for treating lupus nephritis (terminated appraisal) (TA806)

    NICE is unable to make a recommendation on belimumab (Benlysta) for treating lupus nephritis. This is because GlaxoSmithKline did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Technology appraisal guidance
    Published
    13 July 2022

    Sections for TA806

  3. Belimumab for treating active autoantibody-positive systemic lupus erythematosus (TA752)

    Evidence-based recommendations on belimumab (Benlysta) for treating active autoantibody-positive systemic lupus erythematosus.

    Technology appraisal guidance
    Published
    15 December 2021
    View recommendations

    Sections for TA752

  4. Belimumab for treating active autoantibody-positive systemic lupus erythematosus (TA397)

    This guidance has been updated and replaced by NICE technology appraisal guidance 752.

    Technology appraisal guidance
    Published
    22 June 2016

  5. Belimumab with rituximab for treating systemic lupus erythematosus [ID3967]

    Awaiting development [GID-TA10869] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Subcutaneous belimumab for treating systemic lupus erythematosus in children aged 5 to 17 TS ID 11828

      Status ...

    Technology appraisal guidance
    Topic selection